A Novel Cell-Based Assay for Ubiquitin Drug Discovery
Ubiquitin (Ub) is an abundant regulatory polypeptide involved in most cellular processes, added to proteins through a process known as ubiquitylation. The dysregulation or subversion of ubiquitin pathways has been implicated in conditions including viral infection, hereditary neurodegenerative diseases and cancer.
Read MoreKeys to Successful Cell-Based Assay Development with Scalable Electroporation
MaxCyte® is a pioneer in electroporation technology for mammalian cell engineering, combining optimized protocols, reagents and consumables to deliver reproducible performance with minimal cell disturbance. MaxCyte’s static and Flow Electroporation® enable high transfection efficiency in virtually any cell type, with seamless scalability from 75,000 to 200 billion cells. MaxCyte’s electroporation technology can be used to produce Assay Ready Cells, addressing the time and cost of assay development with stable cells. The use of Assay Ready Cells facilitates the expression of toxic proteins and enables assay development in physiologically relevant cell types, including primary cells, stem cells and cells of hematopoietic origin.
Read MoreHigh-Throughput Screening of Ion Channel Variants Using Automated Patch Clamp Recordings in Assay Ready Cells
In the ground-breaking study summarized here, the authors presented a method for the high-throughput evaluation of the functional consequences of KCNQ2 ion channel variants.1 The technique was used to characterize 39 previously unstudied epilepsy-associated Q2 variants and their responses to treatment with a candidate therapeutic.
Read MoreMaxCyte® Flow Electroporation® for Gram-Scale Transient Antibody Production in CHO-S Cells
Discover how MaxCyte® Electroporation, a fully scalable technology, enables high-titer antibody production by transient gene expression in CHO-S cells without requiring specific expression constructs, adapted CHO lines, specialized reagents or media additives. Explore how small-scale electroporation was used to identify optimal conditions that could be applied to large-scale transfection without loss of productivity or the need for further optimization.
Read MoreKeys to Successful Cell-Based Assay Development with Scalable Electroporation
Drug discovery and development is a costly, time-consuming process with a high risk of failure. One approach to save time and mitigate risk is to increase the use of cell-based assays as an alternative to biochemical assays. Cell-based assays (2D and 3D) enable interrogation of a target in a physiological context and have the potential to be used in all phases from target discovery up to preclinical development.
Read MoreMaxCyte® Flow Electroporation Enables Immunocytokine Development
“A novel class of fusion proteins called immunocytokines (ICKs) are an exciting new cancer therapy. They combine antibody specificity with the therapeutic efficacy of cytokines. Learn how MaxCyte® Flow Electroporation® technology streamlined ICK manufacturing and is helping accelerate it into the clinic.”
Read MoreRapid Production of Cells for Screening Voltage-Gated Ion Channels in Automated Electrophysiology Assays Using the MaxCyte® STX™ Scalable Transfection System
Comprising a family with hundreds of members, ion channels represent one of the largest classes of drug targets. Recent advances in automated electrophysiology instrumentation have led to the routine implementation of high throughput assays for screening ion channel modulators.
Read MoreLiterature Review: CHO versus HEK Cell Glycosylation
Choosing a host system for the expression of recombinant proteins should be carefully evaluated prior to the initiation of any biotherapetuic development programs.
Read MoreGram Scale Transient Antibody Production and Stable Cell Line Generation Using Flow Electroporation™ Technology
In recent years researchers have turned to transient gene expression (TGE) as an alternative to CHO stable cell line production for early stage antibody development (1,2).
Read MoreFlow Electroporation Capabilities and Case Studies: Rapid GPCR Screening and Functional Ion Channel Assays.
MaxCyte’s proprietary flow electroporation technology has been successfully applied in ex vivo cell therapy (1) and drug discovery pipelines where reproducibility, efficiency and the need for increased cell numbers are critical.
Read More
